Findings

What do systematic reviews say?

5 questions · 7 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 57.1%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 2 · 28.6%High 0 · 0%

Heparin vs placebo

Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Unfractionated heparin vs no thromboprophylaxis

Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy

Unfractionated heparin showed no clear difference in clinically relevant bleeding compared with no thromboprophylaxis (low certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 2.01 [0.18, 21.96]
1 study · 277 participants
Low

Low molecular weight heparin vs no thromboprophylaxis

Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin probably leads to higher clinically relevant bleeding compared with no thromboprophylaxis (moderate certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 3.4 [1.2, 9.63]
4 studies · 3105 participants
Moderate

Low molecular weight heparin vs active control

Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy

The review found no eligible studies for this question.

3 findings from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ultra‐low‐molecular‐weight heparin vs placebo

Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy

Ultra‐low‐molecular‐weight heparin showed no clear difference in clinically relevant bleeding compared with placebo (moderate certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 1.4 [0.9, 2.19]
1 study · 3172 participants
Moderate